In-silico Screening of Novel Drug Against Ovarian Cancer by Phytochemicals from Carica Papaya

Abstract

Most of the women population suffer from many kinds of reproductive health issues. The cause of the diseases may be genetic or acquired causes. Ovarian cancer is a genetic aberration caused in females generation after generation. Various genes cause the genetic disorder, mainly BRCA 1 and BRCA 2. These major genes are present in chromosome 17q. 77% of the epithelial ovarian cancer tumor genes are in chromosome 17q. The disorder can be a germline mutation in females who express this disease before age 30. By DNA sequencing technology, the functioning of BRCA1 and BRCA2 can be discovered along with the involvement of the additional genes that compromise the homologous recombination (HR) pathway. Epithelial ovarian cancer (EOC) is the deadliest gynecological cancer and presents a major clinical challenge due to limited treatment options. Folate receptor alpha (FRα), encoded by the FOLR1 gene in chromosome 11q13.4, is an attractive therapeutic target due to its prevalent and high expression in EOC cells. The folate receptors FOLR1 and FOLR2 are overexpressed in multiple cancers. The overexpression of FOLR1 is often associated with increased cancer progression and poor patient prognosis. There is emerging evidence that FOLR1 is involved in signaling pathways that are independent of one-carbon metabolism.